Drug profile · INN
ciltacabtagene autoleucel
CARVYKTI
ciltacabtagene autoleucel (CARVYKTI) is a tumor necrosis factor receptor superfamily member 17 binding agent.
Drug details — ciltacabtagene autoleucel
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
ciltacabtagene autoleucel (CARVYKTI) is a tumor necrosis factor receptor superfamily member 17 binding agent.
Key facts
Mechanism of action
Tumor necrosis factor receptor superfamily member 17 binding agent
Primary target: Tumor necrosis factor receptor superfamily member 17
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO
Legend Biotech has presented significant new data at ASCO 2026, showcasing updated survival and safety results for its multiple myeloma therapy CARVYKTI from the CARTITUDE-4 study. The company also unveiled first-in-human data for its investigational CAR-T cell therapy, LB2102, targeting solid tumors.
CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
This article examines the implications of cross-border healthcare policies on CAR-T therapies for cancer, highlighting access challenges and opportunities in the EU.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ciltacabtagene autoleucel?
ciltacabtagene autoleucel (CARVYKTI) is a tumor necrosis factor receptor superfamily member 17 binding agent.
What is the brand name for ciltacabtagene autoleucel?
CARVYKTI is a marketed brand name for ciltacabtagene autoleucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.